AutoPVS1

AutoPVS1 automates interpretation of null (loss-of-function) variants to assign ACMG/AMP PVS1 pathogenicity strengths using ClinGen Sequence Variant Interpretation (SVI) refinements.

Key Features:

• PVS1-focused assessment: Evaluates null (loss-of-function) variants in the human genome specifically for the ACMG/AMP PVS1 criterion.
• ClinGen SVI integration: Implements the ClinGen Sequence Variant Interpretation (SVI) Working Group refinements from 2018 for PVS1 application.
• Validation concordance: Demonstrated 93% concordance with manual interpretations from ClinGen SVI (52 out of 56 manually curated variants).
• Large-scale analysis: Assessed 28,586 putative loss-of-function variants to quantify PVS1 strength outcomes at scale.
• Outcome quantification: Identified that 27.7% of analyzed variants did not meet very strong PVS1, with 17.5% due to variant-specific issues and 10.2% due to disease mechanism considerations.
• Variant-type adjustment: Reports decreases in preliminary PVS1 strength by variant class: splicing 41.0%, frameshift 13.2%, and nonsense 10.8%.
• Reproducible PVS1 strength assignment: Produces reproducible PVS1 strength levels while accounting for variant-specific issues and disease mechanisms.

Scientific Applications:

• Clinical variant interpretation: Assigns PVS1 strength to support ACMG/AMP-based pathogenicity classification of null variants.
• High-throughput reclassification: Enables large-scale evaluation and reclassification of putative loss-of-function variants across datasets.
• Variant-type impact analysis: Quantifies differential effects of splicing, frameshift, and nonsense variants on PVS1 strength.
• Curation support for mechanistic evaluation: Informs consideration of variant-specific issues and disease mechanism in PVS1 determinations.

Methodology:

Implements ClinGen SVI 2018 PVS1 refinements, validated by concordance comparison to ClinGen SVI manual curation (52/56), and performed a large-scale analysis of 28,586 putative loss-of-function variants with summary statistics of PVS1 outcomes.